Day 1 : 2 September 2023 Saturday
Start Time (Hong King Time)	End Time (Hong King Time)	Duration (In Mins)	Session Type	Speaker	Moderator/ Session Chair	Title of Presentation
13:25	13:30	0:05	Welcome	William FOO
Session 1: GI and Hepatobiliary
13:30	13:40	0:10	Presentation	Johnny K S Lau	Dr K O Lam	FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
13:40	13:50	0:10	Presentation	K Yamazaki, Japan		Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.
13:50	14:00	0:10	Presentation	Masanori Terashima, Japan		ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.
14:00	14:10	0:10	Presentation	Eileen O'Reilly, USA		Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.
14:10	14:20	0:10	Presentation	Jianwei Zhang, China		Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.
14:20	14:30	0:10	Presentation	K O Lam		PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
14:30	14:40	0:10	Presentation	Thiery Conroy, France		Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
14:40	14:50	0:10	Presentation	Masatoshi Kudo		Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.
14:50	15:05	0:15	Panel Discussion, Q&A
Session 2: Lung Cancer
15:05	15:15	0:10	Presentation	Yi-Long Wu, China	Dr Oscar Chan	Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
15:15	15:25	0:10	Presentation	Yasushi Goto, Japan		TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
15:25	15:35	0:10	Presentation	Oscar Chan		OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIA NSCLC
15:35	15:45	0:10	Presentation	Quincy S. Chu, Canada		IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
15:45	15:55	0:10	Presentation	James Chih-Hsin Yang, China		Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
15:55	16:05	0:10	Presentation	Conrad Lee		Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.
16:05	16:15	0:10	Presentation	Heather Wakele, USA		KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
16:15	16:30	0:15	Panel Discussion, Q&A
Session 3: Head and Neck Cancer
16:30	16:40	0:10	Presentation	David Johnson	Prof Brigette Ma	Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
16:40	16:50	0:10	Presentation	James Chow		Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.
16:50	17:00	0:10	Presentation	Dr. Liu Xu		PD-1 blockade with Sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM)
17:00	17:15	0:15	Panel Discussion, Q&A
Day 2 : 3 September 2023 Sunday
Start Time (Hong King Time)	End Time (Hong King Time)	Duration (In Mins)	Session Type	Speaker	Moderator/ Session Chair	Title of Presentation
Session 4: Breast Cancer
10:00	10:10	0:10	Presentation	Ann Chan	Prof Roger Ngan	Efficacy and safety results by age in monarche: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
10:10	10:20	0:10	Presentation	Roland Leung		Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.
10:20	10:30	0:10	Presentation	Joanne Chiu		Racial/ethnic differences in 21-gene recurrence score and survival among estrogen receptor-positive breast cancer patients.
10:30	10:40	0:10	Presentation	Cynthia Yeung		Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.
10:40	10:50	0:10	Presentation	Sara Tolaney, USA		Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).
10:50	11:00	0:10	Presentation	NG Ting Ying		Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.
11:00	11:10	0:10	Presentation	William FOO		Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.
11:10	11:20	0:10	Presentation	Kenneth Li		3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).
11:20	11:35	0:15	Panel Discussion, Q&A
11:35	12:20	0:45	GILEAD Sponsored Session	Joline Lim		Sacituzumab Govitecan – A new paradigm for metastatic breast cancer
Session 5 : Genitourinary Cancer — Kidney and Bladder | Prostate, Testicular and Penile
12:20	12:30	0:10	Presentation	FY Cheung	Dr FY Cheung	TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
12:30	12:40	0:10	Presentation	Martin Lam		Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
12:40	12:50	0:10	Presentation	Darren Poon		Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
12:50	13:00	0:10	Presentation	Angus Leung		Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
13:00	13:15	0:15	Panel Discussion, Q&A
Session 6: Gynaecologic Cancer
13:15	13:25	0:10	Presentation	Philip Wu	Dr William Foo	KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
13:25	13:35	0:10	Presentation	Winnie Yip		Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
13:35	13:45	0:10	Presentation	K Y Tse		Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.
13:45	14:00	0:15	Panel Discussion, Q&A
14:00	14:15	0:15	CLOSING REMARKS